Search
Adial Pharmaceuticals Inc
ADILAdd to Watchlist
4.080USD
-0.120-2.86%
Market hours 09/23, 14:01（ET）
10.53MMarket Cap
LossP/E TTM
About Adial Pharmaceuticals Inc Company
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Adial Pharmaceuticals Inc Profile
Ticker SymbolADIL
Company nameAdial Pharmaceuticals Inc
IPO dateJul 27, 2018
CEOClaiborne (Cary J)
Number of employees5
Security typeOrdinary Share
Fiscal year-endJul 27
Address1180 Seminole Trail
CityCHARLOTTESVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code22901
Phone14344229800
Websitehttps://www.adialpharma.com/
Ticker SymbolADIL
IPO dateJul 27, 2018
CEOClaiborne (Cary J)
Company Executives of Adial Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Matthew (Matt) Davidson, Ph.D.
Dr. Matthew (Matt) Davidson, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
65.07K
-351.89%
Dr. Matthew (Matt) Davidson, Ph.D.
Dr. Matthew (Matt) Davidson, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
65.07K
-351.89%
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.42K
--
Mr. Tony Goodman
Mr. Tony Goodman
Chief Operating Officer, Director
Chief Operating Officer, Director
26.52K
--
Mr. Vinay Shah
Mr. Vinay Shah
Chief Financial Officer
Chief Financial Officer
17.32K
--
Mr. Kevin Schuyler
Mr. Kevin Schuyler
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
9.22K
+0.04%
Mr. Kevin Schuyler
Mr. Kevin Schuyler
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
9.22K
+0.04%
Mr. J. Kermit Anderson
Mr. J. Kermit Anderson
Independent Director
Independent Director
--
--
Mr. Robertson H. Gilliland
Mr. Robertson H. Gilliland
Independent Director
Independent Director
--
--
Ms. Wendy B. Young, Ph.D.
Ms. Wendy B. Young, Ph.D.
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Matthew (Matt) Davidson, Ph.D.
Dr. Matthew (Matt) Davidson, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
65.07K
-351.89%
Dr. Matthew (Matt) Davidson, Ph.D.
Dr. Matthew (Matt) Davidson, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
65.07K
-351.89%
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.42K
--
Mr. Tony Goodman
Mr. Tony Goodman
Chief Operating Officer, Director
Chief Operating Officer, Director
26.52K
--
Mr. Vinay Shah
Mr. Vinay Shah
Chief Financial Officer
Chief Financial Officer
17.32K
--
Mr. Kevin Schuyler
Mr. Kevin Schuyler
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
9.22K
+0.04%
FAQs
Who are the top five shareholders of Adial Pharmaceuticals Inc?
The top five shareholders of Adial Pharmaceuticals Inc are: Dr. Matthew (Matt) Davidson, Ph.D.
How many institutions hold shares of Adial Pharmaceuticals Inc (ADIL)?
As of 2026Q1, 34 institutions hold shares of Adial Pharmaceuticals Inc, with a combined market value of approximately 141.23K, accounting for 9.89% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 100332.00.